Literature DB >> 30151604

Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients.

Licia Grazzi1, Eleonora Grignani2, Domenico D'Amico3, Emanuela Sansone3, Alberto Raggi2.   

Abstract

PURPOSE OF REVIEW: The aim is twofold. First, to give an insight on the role exerted by different classes of drugs in favouring migraine chronification. Second, to explore the relationship between type and amount of overused medications and history of previous withdrawal treatment and of frequent relapses. RECENT
FINDINGS: All drug classes were found to favour migraine chronification. No data are available for the association with relapses into CM-MOH. Our clinical study shows that patients who underwent previous withdrawal treatments were more likely to be overusers of multiple drug classes and overuse higher amounts of symptomatic medications, particularly, indomethacin, eletriptan and tramadol. Frequent relapsers were more likely to be overusers of opioids or ergotamine and caffeine derivates or of multiple classes, particularly acetylsalicylic acid and ergotamine/caffeine derivates. The joint results our review and clinical study do not seem to support the idea that MOH is drug-specific: rather, it points out that all drug classes may induce migraine chronification. Those drugs which are at higher risk of overuse are among those preferred by the "worst" patients, i.e. those who needed one or more withdrawal treatments for MOH. Our results reinforce the clinical impression that patients with CM and MOH, and particularly the most difficult to treat for their poor response to withdrawal treatments, are characterised by a particular drive towards the consumption of "whatever is likely to be perceived to provide some relief", despite these drugs that are perceived as "more powerful", are often indicated as second- or third-line medications.

Entities:  

Keywords:  Anti-inflammatory drugs; Chronic migraine; Medication-overuse headache; Opioids; Triptans; Withdrawal

Mesh:

Substances:

Year:  2018        PMID: 30151604     DOI: 10.1007/s11916-018-0729-x

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  64 in total

1.  The case for opiate/opioid therapy in the management of headache.

Authors:  John F Rothrock
Journal:  Headache       Date:  2012-05       Impact factor: 5.887

2.  Gender and education inequalities in the cost of medication-overuse headache.

Authors:  Alberto Raggi; Matilde Leonardi; Chiara Scaratti; Emanuela Sansone; Licia Grazzi; Domenico D'Amico
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

3.  Generalized Pressure Pain Hypersensitivity in the Cervical Muscles in Women with Migraine.

Authors:  Lidiane Lima Florencio; Maria Carolina Merli Giantomassi; Gabriela Ferreira Carvalho; Maria Cláudia Gonçalves; Fabíola Dach; César Fernández-de-Las-Peñas; Débora Bevilaqua-Grossi
Journal:  Pain Med       Date:  2015-04-30       Impact factor: 3.750

Review 4.  Efficacy of fixed combinations of acetylsalicyclic acid, acetaminophen and caffeine in the treatment of idiopathic headache: a review.

Authors:  K Anneken; S Evers; I W Husstedt
Journal:  Eur J Neurol       Date:  2010-01-13       Impact factor: 6.089

5.  Is β endorphin related to migraine headache and its relief?

Authors:  Usha K Misra; Jayantee Kalita; Gyanesh M Tripathi; Sanjeev K Bhoi
Journal:  Cephalalgia       Date:  2013-01-11       Impact factor: 6.292

6.  Family history for chronic headache and drug overuse as a risk factor for headache chronification.

Authors:  Sabina Cevoli; Elisa Sancisi; Daniela Grimaldi; Giulia Pierangeli; Stefano Zanigni; Marianna Nicodemo; Pietro Cortelli; Pasquale Montagna
Journal:  Headache       Date:  2009-03       Impact factor: 5.887

Review 7.  Overuse of acute migraine medications and migraine chronification.

Authors:  Marcelo E Bigal; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2009-08

8.  Altered Brain Structure and Function Correlate with Disease Severity and Pain Catastrophizing in Migraine Patients.

Authors:  Catherine S Hubbard; Shariq A Khan; Michael L Keaser; Vani A Mathur; Madhav Goyal; David A Seminowicz
Journal:  eNeuro       Date:  2014-12-30

9.  Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial.

Authors:  Tomi Ashaye; Natalia Hounsome; Dawn Carnes; Stephanie J C Taylor; Kate Homer; Sandra Eldridge; Anne Spencer; Anisur Rahman; Jens Foell; Martin R Underwood
Journal:  BMJ Open       Date:  2018-06-06       Impact factor: 2.692

Review 10.  Opioid resistance in chronic daily headache: a synthesis of ideas from the bench and bedside.

Authors:  David M Biondi
Journal:  Curr Pain Headache Rep       Date:  2003-02
View more
  5 in total

1.  Is there a sex difference in adult salivary clearance of caffeine (1,3,7-trimethylpurine-2,6-dione)?

Authors:  Basant K Puri; Christopher R Heard; Jean A Monro
Journal:  J Oral Biol Craniofac Res       Date:  2020-02-06

2.  Pain rates in general population for the period 1991-2015 and 10-years prediction: results from a multi-continent age-period-cohort analysis.

Authors:  Davide Guido; Matilde Leonardi; Blanca Mellor-Marsá; Maria V Moneta; Albert Sanchez-Niubo; Stefanos Tyrovolas; Iago Giné-Vázquez; Josep M Haro; Somnath Chatterji; Martin Bobak; Jose L Ayuso-Mateos; Holger Arndt; Ilona Koupil; Jerome Bickenbach; Seppo Koskinen; Beata Tobiasz-Adamczyk; Demosthenes Panagiotakos; Alberto Raggi
Journal:  J Headache Pain       Date:  2020-05-13       Impact factor: 7.277

Review 3.  The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.

Authors:  Willem Sebastiaan van Hoogstraten; Antoinette MaassenVanDenBrink
Journal:  J Headache Pain       Date:  2019-05-16       Impact factor: 7.277

4.  Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache.

Authors:  Edita Navratilova; Sasan Behravesh; Janice Oyarzo; David W Dodick; Pradeep Banerjee; Frank Porreca
Journal:  Cephalalgia       Date:  2020-07-02       Impact factor: 6.292

5.  Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache.

Authors:  Jill C Rau; Edita Navratilova; Janice Oyarzo; Kirk W Johnson; Sheena K Aurora; Todd J Schwedt; David W Dodick; Frank Porreca
Journal:  Cephalalgia       Date:  2020-06-24       Impact factor: 6.292

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.